122 related articles for article (PubMed ID: 20584716)
1. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease.
Sugita S; Yamada Y; Mochizuki M
Br J Ophthalmol; 2011 Apr; 95(4):549-52. PubMed ID: 20584716
[TBL] [Abstract][Full Text] [Related]
2. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha.
Evereklioglu C; Borlu M
Br J Ophthalmol; 2008 Aug; 92(8):1034, 1148-9. PubMed ID: 18653594
[No Abstract] [Full Text] [Related]
3. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
4. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
[TBL] [Abstract][Full Text] [Related]
5. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
[TBL] [Abstract][Full Text] [Related]
6. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
[TBL] [Abstract][Full Text] [Related]
7. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.
Ternant D; Mulleman D; Degenne D; Willot S; Guillaumin JM; Watier H; Goupille P; Paintaud G
Ther Drug Monit; 2006 Apr; 28(2):169-74. PubMed ID: 16628126
[TBL] [Abstract][Full Text] [Related]
8. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Kawaguchi T; Mochizuki M
Br J Ophthalmol; 2010 Mar; 94(3):284-8. PubMed ID: 19692382
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of infliximab on the acute attack of uveitis.
Alokaily F; Alsaleh S; Al-Balawi M; Al-Rashidi S
Saudi Med J; 2010 Jan; 31(1):82-5. PubMed ID: 20062906
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis.
El-Shabrawi Y; Hermann J
Ophthalmology; 2002 Dec; 109(12):2342-6. PubMed ID: 12466181
[TBL] [Abstract][Full Text] [Related]
11. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
Ebert EC; Das KM; Mehta V; Rezac C
Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
[TBL] [Abstract][Full Text] [Related]
12. Intraocular cytokine environment in active Behçet uveitis.
Ahn JK; Yu HG; Chung H; Park YG
Am J Ophthalmol; 2006 Sep; 142(3):429-34. PubMed ID: 16935587
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
14. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
Svenson M; Geborek P; Saxne T; Bendtzen K
Rheumatology (Oxford); 2007 Dec; 46(12):1828-34. PubMed ID: 18032541
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study.
Méric JC; Mulleman D; Ducourau E; Lauféron F; Miow Lin DC; Watier H; Goupille P; Paintaud G
Ther Drug Monit; 2011 Aug; 33(4):411-6. PubMed ID: 21743380
[TBL] [Abstract][Full Text] [Related]
16. Alopecia areata universalis during off-label treatment with Infliximab in a patient with Behçet disease.
Beccastrini E; Squatrito D; Emmi G; Fabbri P; Emmi L
Dermatol Online J; 2010 Sep; 16(9):15. PubMed ID: 20875336
[TBL] [Abstract][Full Text] [Related]
17. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.
Okada AA; Goto H; Ohno S; Mochizuki M;
Arch Ophthalmol; 2012 May; 130(5):592-8. PubMed ID: 22652845
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
19. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab.
Iwata D; Namba K; Mizuuchi K; Kitaichi N; Kase S; Takemoto Y; Ohno S; Ishida S
Graefes Arch Clin Exp Ophthalmol; 2012 Jul; 250(7):1081-7. PubMed ID: 22234352
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
